Market closed
Dynavax/$DVAX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Dynavax
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Ticker
$DVAX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
408
Website
Dynavax Metrics
BasicAdvanced
$1.7B
66.65
$0.20
1.32
-
Price and volume
Market cap
$1.7B
Beta
1.32
52-week high
$13.44
52-week low
$9.74
Average daily volume
1.8M
Financial strength
Current ratio
10.796
Quick ratio
9.679
Long term debt to equity
41.931
Total debt to equity
42.63
Interest coverage (TTM)
0.13%
Management effectiveness
Return on assets (TTM)
0.06%
Return on equity (TTM)
4.48%
Valuation
Price to earnings (TTM)
66.65
Price to revenue (TTM)
6.253
Price to book
2.8
Price to tangible book (TTM)
2.81
Price to free cash flow (TTM)
28.815
Growth
Revenue change (TTM)
19.36%
Earnings per share change (TTM)
-500.00%
3-year revenue growth (CAGR)
-14.23%
3-year earnings per share growth (CAGR)
-29.43%
What the Analysts think about Dynavax
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Dynavax stock.
Dynavax Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Dynavax Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Dynavax News
AllArticlesVideos
Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call Transcript
Seeking Alpha·3 days ago
Exclusive: Investor Deep Track launches proxy fight at Dynavax, nominates 4 directors
Reuters·5 days ago
Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty
Benzinga·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Dynavax stock?
Dynavax (DVAX) has a market cap of $1.7B as of February 24, 2025.
What is the P/E ratio for Dynavax stock?
The price to earnings (P/E) ratio for Dynavax (DVAX) stock is 66.65 as of February 24, 2025.
Does Dynavax stock pay dividends?
No, Dynavax (DVAX) stock does not pay dividends to its shareholders as of February 24, 2025.
When is the next Dynavax dividend payment date?
Dynavax (DVAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Dynavax?
Dynavax (DVAX) has a beta rating of 1.32. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.